Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

miRNAs and Target Genes in Breast Cancer MetastasisClinical Perspectives: Breast Cancer Brain Metastasis

miRNAs and Target Genes in Breast Cancer Metastasis: Clinical Perspectives: Breast Cancer Brain... [The incidence of central nervous system metastasis from primary breast cancer has steadily increased with aggressive chemotherapy resulting in improved long-term survival. Brain metastases are more common among those with more aggressive histological subtypes of breast cancer such as triple negative and HER2-positive subtypes. Effectiveness of pharmacological treatment for brain metastases is hindered by the blood–brain barrier. As such, current standard-of-care treatment modalities for CNS metastases include microsurgical resection, whole-brain radiation therapy, and stereotactic radiosurgery, either alone or in combination. Despite providing good local control, involvement of the CNS remains a devastating complication of breast cancer significantly limiting patient survival and quality of life. Leptomeningeal disease is a particularly devastating neurological complication of breast cancer and has limited treatment options. Overall prognosis of breast cancer brain metastasis remains dismal with 1- and 2-year survival rates of 20 % and 2 %, respectively. Clearly, there is a dire need to identify biomarkers permitting earlier and accurate diagnosis of CNS metastases, development of prevention strategies in high-risk individuals, and establishing more effective treatment options such as targeted systemic and intrathecal therapies.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

miRNAs and Target Genes in Breast Cancer MetastasisClinical Perspectives: Breast Cancer Brain Metastasis

Download PDF
15 pages

Loading next page...
 
/lp/springer-journals/mirnas-and-target-genes-in-breast-cancer-metastasis-clinical-kHiyeZ00JH

References (74)

Publisher
Springer International Publishing
Copyright
© Springer International Publishing Switzerland 2014
ISBN
978-3-319-08161-8
Pages
37 –51
DOI
10.1007/978-3-319-08162-5_4
Publisher site
See Chapter on Publisher Site

Abstract

[The incidence of central nervous system metastasis from primary breast cancer has steadily increased with aggressive chemotherapy resulting in improved long-term survival. Brain metastases are more common among those with more aggressive histological subtypes of breast cancer such as triple negative and HER2-positive subtypes. Effectiveness of pharmacological treatment for brain metastases is hindered by the blood–brain barrier. As such, current standard-of-care treatment modalities for CNS metastases include microsurgical resection, whole-brain radiation therapy, and stereotactic radiosurgery, either alone or in combination. Despite providing good local control, involvement of the CNS remains a devastating complication of breast cancer significantly limiting patient survival and quality of life. Leptomeningeal disease is a particularly devastating neurological complication of breast cancer and has limited treatment options. Overall prognosis of breast cancer brain metastasis remains dismal with 1- and 2-year survival rates of 20 % and 2 %, respectively. Clearly, there is a dire need to identify biomarkers permitting earlier and accurate diagnosis of CNS metastases, development of prevention strategies in high-risk individuals, and establishing more effective treatment options such as targeted systemic and intrathecal therapies.]

Published: Sep 6, 2014

Keywords: Brain metastases; Blood–brain barrier; Central nervous system; Treatment; Surgery; Radiosurgery; Whole-brain radiation therapy; Leptomeningeal disease; Clinical trials

There are no references for this article.